PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of germs or bacteria called pneumococcus (pronounced new-mo-kock-us). For more information, see Section 1.

Additionally, Capvaxive is recommended for adults aged 50 and older who have not received any PCV or whose previous vaccination history is unknown. Adults aged 65 and older may receive Capvaxive if ...

In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

The flu vaccine is a must for anyone over 60. Influenza can be more severe in older adults, often leading to complications like pneumonia. According to the Centers for Disease Control and Prevention ...

Anticipated growth for ‘Saudi Arabia 23 Valent Pneumococcal Polysaccharide Vaccine Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

3 According to the World Health Organization, there are two classes of pneumococcal vaccines currently available, with one based on olysaccharides and the other based on polysaccharides conjugated to ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.